2016 | Philochem

Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CA

by last | Dec 13, 2016 | 2016, Press Releases

PR_Philogen_13_12_2016

Philogen S.p.A. announces participation in the “World Immunotherapy Congress 2016”, 14 – 16 November 2016, Basel, Switzerland

by last | Nov 1, 2016 | 2016, Press Releases

Press_release_1_November_2016

Philogen S.p.A announces participation in “PEGS Europe – Protein & Antibody Engineering Summit” , 31 October – 4 November 2016, Lisbon, Portugal

by last | Oct 31, 2016 | 2016, Press Releases

PR Philogen 31 October 2016

Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.

by last | Oct 28, 2016 | 2016, Press Releases

PR Philogen 281016

Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”, 28 August – 1 September 2016, Manchester, UK

by last | Aug 11, 2016 | 2016, Press Releases

Press release_Philogen 11 August 2016

Philogen S.p.A. announced that they have entered into a collaboration

by last | Aug 3, 2016 | 2016, Press Releases

Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics....

« Older Entries